Latest Human Genome Sciences Stories
ROCKVILLE, Maryland and LONDON, July 20 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE). In the placebo-controlled BLISS-52 study, the results showed that belimumab plus standard of care achieved a clinically and...
ROCKVILLE, Md., July 9 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced publication by The New England Journal of Medicine of the results of two pivotal animal efficacy studies, which showed the life-saving potential of the Company's human monoclonal antibody drug raxibacumab (ABthrax(TM)), as well as the results of human safety studies, which supported the use of raxibacumab in the event of life-threatening inhalation anthrax disease. (Logo:...
ROCKVILLE, Maryland, July 1 /PRNewswire-USNewswire/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it expects to have top-line results available on Monday, July 20, from BLISS-52, the first of two pivotal Phase 3 clinical trials of BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) in systemic lupus erythematosus (SLE). (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) Senior management will host a conference call to discuss the results on Monday, July...
ROCKVILLE, Md., June 19 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that its presentation at the 2009 Piper Jaffray Europe Conference will be webcast and may be accessed at www.hgsi.com. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) A member of Human Genome Sciences' senior management team will present a corporate overview on Tuesday, June 23, 2009 at 10:30 am GMT (6:30 am Eastern Time). Investors interested in listening to the...
- Trial conducted by Novartis evaluating safety and efficacy of Albuferon administered every four weeks in combination with ribavirin in patients with genotypes 2 and 3 hepatitis C - ROCKVILLE, Md., June 19 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Novartis has completed enrollment and initial dosing in a Phase 2b clinical trial to evaluate the safety and efficacy of Albuferon(R) (albinterferon alfa-2b) administered monthly in combination...
- Phase 2 continuation data demonstrated sustained improvement in disease activity and patient response rate through four years of BENLYSTA therapy - - Frequency of disease flares as measured by the SELENA SLEDAI flare index and by BILAG A or B organ domain scores decreased over four years of BENLYSTA therapy - - No increase in overall adverse events, serious adverse events, malignancies or serious infections over time - ROCKVILLE, Md., June 11 /PRNewswire-FirstCall/ -- Human Genome...
ROCKVILLE, Md., June 8 /PRNewswire-FirstCall/ -- Attached is a press release issued yesterday by GlaxoSmithKline (GSK), regarding new Phase 2 data for Syncria(R) (albiglutide) presented at the American Diabetes Association 69th Scientific Sessions in New Orleans. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) Syncria is a biological product generated from the genetic fusion of human albumin and modified human GLP-1 peptide, and is designed to act throughout...
- First-in-class treatment for inhalation anthrax - ROCKVILLE, Md., May 21 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its human monoclonal antibody drug ABthrax(TM) (raxibacumab) for the treatment of inhalation anthrax. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) The BLA submission includes the results of two...
ROCKVILLE, Md. and NOTTINGHAM, UK, May 7 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) and Novozymes Biopharma, a part of Novozymes (Nasdaq: NZYM B), today announced that they have amended an existing license agreement to allow both companies to expand application of their proprietary albumin fusion technology. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO) Under the amended agreement, HGS and Novozymes each has the opportunity to exclusively license...
- First HGS product sales achieved with delivery of ABthrax(TM) to U.S. Strategic National Stockpile - - $177 million in first quarter revenues; cash balance of $397 million as of March 31, up $24 million from year-end 2008 - - Positive results for second Phase 3 trial of Albuferon(R) in chronic hepatitis C; global marketing applications planned in fall 2009 - - Initiation of Syncria(R) Phase 3 program brings $9 million milestone payment from GSK - ROCKVILLE, Md., April 29...
